Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

GE to Expand in Biomedical and Life Sciences with Strategic Acquisitions from Thermo Fisher Scientific

By BiotechDaily International staff writers
Posted on 15 Jan 2014
General Electric (GE; Fairfield, CT, USA) and Thermo Fisher Scientific (Waltham, MA, USA) have entered into an agreement for GE’s subsidiary GE Healthcare (Little Chalfont, UK) to acquire cell culture media and sera, gene modulation, and magnetic beads businesses from Thermo Fisher for approximately USD 1.06 billion. The three businesses to be acquired generated combined annual revenues of approximately USD 250 million in 2013.

GE Healthcare’s leadership in medical diagnostic technology includes its USD 4 billion life sciences business. The acquisition, anticipated to close in early 2014 (subject to regulatory approvals), will allow GE to expand its offering and development of technologies for the discovery and manufacturing of innovative new medicines, cell therapies, vaccines, and diagnostics in the biomedical sector of its growing life sciences division. It will also extend GE’s bioprocessing manufacturing footprint in Asia, the Americas, and Europe.

Thermo Fisher’s HyClone cell culture media and sera products are highly complementary to GE Healthcare’s established technologies for cell biology research and biopharmaceutical manufacturing, enabling GE to offer its customers a substantially wider range of technologies and services. Thermo Fisher’s gene modulation technologies complement GE’s established technologies for drug discovery research, and the Sera-Mag magnetic beads product line extends GE’s existing technologies in protein analysis and medical diagnostics. The complementary product offerings and strong strategic fit of the acquisitions will also enable GE Healthcare to expand and accelerate the development of new “end-to-end” technologies.

“Life sciences is one of our strongest and fastest-growing business areas, driven by the world’s demand for improved diagnostics and new, safer medicines. Combining GE’s engineering expertise with our capabilities in life sciences is already bringing great benefits to industry, research, and patients. This deal [...] will help us realize our vision of bringing better healthcare to more people at lower cost,” said John Dineen, president and CEO, GE Healthcare.

“We look forward to the HyClone cell culture and other businesses joining the GE family. They are a great fit with our key areas of focus, and bring exciting new technologies, enhanced manufacturing capabilities as well as a great group of talented people to help grow our business,” said Kieran Murphy, president and CEO of GE Healthcare’s life sciences division. “In addition to providing us with new approaches to drug discovery and biomedical research, this acquisition is a significant step forward for our customers in biopharmaceutical manufacturing. They will benefit immediately from an expanded range of “start-to-finish” technologies that will help them improve product yields and reduce time-to-market. By expanding our production facilities to three continents, we will be able to offer the biopharmaceutical industry greater confidence in the security of supply of cell culture media and sera.”

Related Links:
General Electric
GE Healthcare
Thermo Fisher Scientific


Channels

Genomics/Proteomics

view channel
Image: The photo shows a mouse pancreatic islet as seen by light microscopy. Beta cells can be recognized by the green insulin staining. Glucagon is labeled in red and the nuclei in blue (Photo courtesy of Wikimedia Commons).

Regenerative Potential Is a Trait of Mature Tissues, Not an Innate Feature of Newly Born Cells

Diabetes researchers have found that the ability of insulin-producing beta cells to replicate and respond to elevated glucose concentrations is absent in very young animals and does not appear until after weaning.... Read more

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.